Company profile: Universal Cells
1.1 - Company Overview
Company description
- Provider of nuclease-free rAAV gene editing technology to create universal donor pluripotent and engineered allogeneic stem cells, and cell production for clinical trials. Develops, licenses and commercializes stem cell therapies designed to overcome immune rejection and enable true off-the-shelf therapeutic products using a proprietary genome editing approach.
Products and services
- Allogeneic Stem Cells: Universal Cells engineers off-the-shelf allogeneic stem cells differentiated into various therapeutic cell types to overcome immune rejection
- Clinical Trial Cell Production: Universal Cells produces clinical-trial-focused cell lots, developing gene editing methods and engineering stem cells for clinical trials
- Gene Editing Technology: Proprietary, nuclease-free recombinant Adeno-Associated Virus (rAAV) gene editing systems create universal donor, pluripotent stem cells overcoming immune rejection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Universal Cells
ArsenalBio
HQ: United States
Website
- Description: Provider of programmable CAR T-cell therapies for solid tumors, using synthetic biology to engineer T cells, including AB-1015 for ovarian cancer with dual antigen-sensing logic gating, AB-2100 for kidney cancer with potency enhancements, and the AB-3000 series for prostate cancer; collaborates with Bristol Myers Squibb and Genentech to advance next-generation T-cell therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArsenalBio company profile →
Histogenics
HQ: United States
Website
- Description: Provider of tissue regeneration treatments for long-lasting joint repair.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Histogenics company profile →
Medistem
HQ: United States
Website
- Description: Provider of adult stem cell-based therapeutic products through development, acquisition, and commercialization. Founded in 2005, the company holds 16 families of patent applications, has numerous scientific publications, and generates revenue by out-licensing certain technologies. Main candidate: Endometrial Regenerative Cell (ERC).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medistem company profile →
HemoGenyx Pharmaceuticals
HQ: United Kingdom
Website
- Description: Provider of cell-based and antibody immunotherapies for blood diseases. Offerings include HEMO-CAR-T, a modified T-cell therapy for Acute Myeloid Leukemia (AML); CDX, a bispecific monoclonal antibody for relapsed/refractory AML and conditioning for bone marrow transplantation; and CBR, an immunotherapy platform to prevent and combat viral infections and certain cancers, with proof of concept for SARS-COV-2.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HemoGenyx Pharmaceuticals company profile →
Creative Medical Technology
HQ: United States
Website
- Description: Provider of regenerative and cell therapy platforms in immunology, urology, neurology, and orthopedics, including ImmCelzTM autologous immune cell therapy; Enhanced Allogenic Platform using perinatal tissue cells; Supercharged Autologous Immunotherapy; Reprogrammed Cell Therapy with iPSCs; Rapid Autologous Therapies, and CaverStem for erectile dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Creative Medical Technology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Universal Cells
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Universal Cells
2.2 - Growth funds investing in similar companies to Universal Cells
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Universal Cells
4.2 - Public trading comparable groups for Universal Cells
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →